Loading...
Conmed Q1 2025 Earnings Report
Conmed reported a revenue increase of 2.9% year over year, reaching $321.3 million, with a constant currency growth of 3.8%. GAAP diluted net earnings per share were $0.19, while adjusted diluted net earnings per share were $0.95.
Key Takeaways
Conmed's Q1 2025 performance showed a revenue increase to $321.3 million, driven by strong constant currency growth. Adjusted diluted EPS saw a significant increase compared to the prior year, despite a decrease in GAAP EPS.
Total revenue for Q1 2025 was $321.3 million, an increase of 2.9% year over year.
Constant currency revenue growth was 3.8% for Q1 2025.
GAAP diluted net earnings per share were $0.19, a decrease from $0.63 in the prior year period.
Adjusted diluted net earnings per share were $0.95, an increase from $0.79 in the prior year period.
Conmed
Conmed
Conmed Revenue by Segment
Conmed Revenue by Geographic Location
Revenue by Segment
Orthopedic Surgery Revenue
CapyFin.comGeneral Surgery Revenue
CapyFin.comSingle-Use Products Revenue
CapyFin.comCapital Products Revenue
CapyFin.comRevenue by Geographic Location
Domestic Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Conmed has updated its financial guidance for 2025, projecting total revenue between $1,350.0 million and $1,378.0 million, and adjusted diluted EPS between $4.31 and $4.46.
Positive Outlook
- Projected total revenue of $1,350.0 million to $1,378.0 million.
- Expected organic constant currency growth for adjusted diluted EPS of ~10% to ~13%.
- Total adjusted diluted EPS (incl. foreign currency impact) expected to be $4.45 to $4.60.
- Total adjusted diluted EPS (incl. foreign currency impact & tariff impact) expected to be $4.31 to $4.46.
- Continued focus on higher-growth, higher-margin offerings.
Challenges Ahead
- Estimated negative foreign currency impact of $(0.15) to $(0.10) on adjusted diluted EPS.
- Estimated negative tariff impact of $(0.14) on adjusted diluted EPS.
- Lower end of revenue guidance implies ~4% constant currency growth.
- Lower end of adjusted diluted EPS guidance (incl. all impacts) implies ~3% growth.
- Uncertainty regarding the impact and timing of acquisition, integration, and other charges.